Neurimmune Holding AG:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7580)
◆英語タイトル:Neurimmune Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7580
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:21
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Neurimmune Holding AG (Neurimmune), formerly Neurimmune Therapeutics AG is a biopharmaceutical company that develops immunotherapeutics for human diseases. The company’s pipeline products include human-derived monoclonal antibodies developed for the treatment and prevention of human neurodegenerative disorders through preclinical development. It develops reverse translational medicine technology platform which creates recombinant human-derived monoclonal antibodies as therapeutics. Neurimmune’s human-derived monoclonal antibodies are used as drug candidates in the treatment of diseases such as Alzheimer’s disease, Parkinson’s disease, central nervous system disorders, transthyretin amyloidosis, type-2 diabetes, tauopathies and amyotrophic lateral sclerosis. The company also conducts research and development programs on progressive multifocal leukoencephalopathy, neuropathy, Huntington’s disease and cardiomyopathy. Neurimmune is headquartered in Zurich, Switzerland.

Neurimmune Holding AG – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurimmune Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
AL-S Pharma Secures Investment from Neurimmune and TVM Capital Life Science Venture Capital 10
Partnerships 11
Biogen Exercises Option Agreement with Neurimmune 11
Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 12
Ramot at Tel Aviv University Enters into Research Agreement with Neurimmune 13
ALS TDI and Anelixis Therapeutics Enters into Research Agreement with Neurimmune 14
Licensing Agreements 15
Mabimmune Enters into Collaborative Research Agreement with Neurimmune 15
Neurimmune Holding AG – Key Competitors 16
Neurimmune Holding AG – Key Employees 17
Neurimmune Holding AG – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Sep 12, 2018: Neurimmune names Christoph Hock as Chief Medical Officer to lead clinical development 19
Apr 26, 2018: Neurimmune appoints Fabian Buller as Chief Business Officer 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Key Facts 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurimmune Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurimmune Holding AG, Deals By Therapy Area, 2012 to YTD 2018 8
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AL-S Pharma Secures Investment from Neurimmune and TVM Capital Life Science Venture Capital 10
Biogen Exercises Option Agreement with Neurimmune 11
Neurimmune Therapeutics Enters into Co-Development Agreement with Ono Pharma 12
Ramot at Tel Aviv University Enters into Research Agreement with Neurimmune 13
ALS TDI and Anelixis Therapeutics Enters into Research Agreement with Neurimmune 14
Mabimmune Enters into Collaborative Research Agreement with Neurimmune 15
Neurimmune Holding AG, Key Competitors 16
Neurimmune Holding AG, Key Employees 17

List of Figures
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Neurimmune Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Neurimmune Holding AG:製薬・医療:M&Aディール及び事業提携情報(Neurimmune Holding AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆